低剂量甲氨蝶呤能否减轻中晚期膝骨关节炎的积液-滑膜炎与症状:随机双盲安慰剂对照试验方案
本方案描述一项多中心随机安慰剂对照试验,计划招募200例中晚期症状性膝骨关节炎且积液-滑膜炎分级≥2的参与者,随机分配至甲氨蝶呤组(按耐受情况从每周5 mg起始,逐步增至每周15 mg)或安慰剂组。主要结局为MRI测量的积液-滑膜炎大小与VAS评估的膝痛,次要结局包括髌下脂肪垫信号强度改变、WOMAC总分及分项与OMERACT-OARSI应答者。
要点
- 针对中晚期膝骨关节炎且积液-滑膜炎分级≥2的症状性患者。
- 甲氨蝶呤按耐受情况从每周5 mg逐步滴定至每周15 mg。
- 主要结局为MRI积液-滑膜炎大小与VAS膝痛。
核心结论
- 若甲氨蝶呤能缓解中晚期膝骨关节炎患者症状并减轻炎症,可能延迟膝关节置换时间,带来显著临床与公共卫生影响。
研究设计与样本
- 多中心随机、双盲、安慰剂对照试验方案,计划招募200例中晚期症状性膝骨关节炎且积液-滑膜炎分级≥2的参与者。
- 参与者随机分配至甲氨蝶呤组或安慰剂组,甲氨蝶呤从每周5 mg起始,按耐受情况逐步增至每周15 mg。
- 同时进行意向性分析与符合方案分析。
主要发现
- 主要结局为MRI测量的积液-滑膜炎大小与VAS评估的膝痛。
- 次要结局包括髌下脂肪垫信号强度改变、WOMAC总分及分项、OMERACT-OARSI应答者。
- 试验注册号ClinicalTrials.gov NCT03815448,注册日期2019年1月21日。
关键数值与推荐
- 纳入条件:中晚期症状性膝骨关节炎且积液-滑膜炎分级≥2。
- 甲氨蝶呤剂量:前2周每周5 mg,第2个2周增至每周10 mg,其余时间按耐受情况增至每周15 mg。
临床怎么用
- 为低剂量甲氨蝶呤用于中晚期膝骨关节炎抗炎与镇痛提供随机对照证据,结果待试验完成后确定。
局限性
- 本文为研究方案,尚无疗效与安全性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteoarthritis (OA) is a common chronic disease in older adults. Currently, there are no effective therapies to reduce disease severity and progression of knee OA (KOA), particularly in mid- to late-stages. This study aims to examine the effect of methotrexate (MTX) on knee effusion-synovitis and pain in symptomatic patients with mid- to late-stage KOA. METHODS/DESIGN: This protocol describes a multicentre randomised placebo-controlled clinical trial aiming to recruit 200 participants with mid- to late-stage symptomatic KOA and with effusion-synovitis grade of ≥ 2. Participants will be randomly allocated to the MTX group (start from 5 mg per week for the first 2 weeks and increase to 10 mg per week for the second 2 weeks and 15 mg per week for the remaining period if tolerated) or the placebo group. Primary outcomes are effusion-synovitis size measured by magnetic resonance imaging (MRI) and knee pain assessed by visual analogue scale (VAS). Secondary outcomes are signal intensity alteration within infrapatellar fat pad (IPFP) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score and subscores, and the Outcome Measures in Rheumatology Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) responders. Both intention-to-treat and per-protocol analyses will be performed. DISCUSSION: If MTX intervention can relieve symptoms and reduce inflammation in patients with mid- to late-stage KOA, it has the potential for significant clinical and public health impact as this low-cost and commonly used intervention would delay the time to knee replacement, leading to substantial cost savings and improve quality of life. TRIAL REGISTRATION: ClinicalTrials.gov NCT03815448 . Registered on 21 January 2019.
引用
- Zhu Z, Yu Q, Leng X, et al. Can low-dose methotrexate reduce effusion-synovitis and symptoms in patients with mid- to late-stage knee osteoarthritis? Study protocol for a randomised, double-blind, and placebo-controlled trial. Trials. 2020. PMID: 32938470. doi:10.1186/s13063-020-04687-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。